Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine – Hepatic Oncology at the University of Barcelona. He is also Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 306 manuscripts in Liver Cancer (citations:77017;h-index:112; IF:4675;). Top 1% most cited researcher globally by Clarivate Analytics (2014-20), President of ILCA (2011-13), Senior Editor CCR, lectured > 605 international meetings and has been the PI of European grants FP7-HEPTROMIC,HEP-CAR, Accelerator Award, NIH-NIDDK R01-award, I+D and competitive private grants. Achievements a) Establishing therapies as standard of care for hepatocellular carcinoma (HCC) –sorafenib, regorafenib and ramucirumab; b) Defining molecular classes of HCC and cholangiocarcinoma (CCA) and c) discovery of drivers as therapeutic targets (i.e mTOR, IGF signalling) for HCC and FGFR2 fusion (CCA).